Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» September 2011
September 2011
Teva Tumbles to Lowest Since 2006 on EU Review of Cephalon
Teva Tumbles to Lowest Since 2006 on EU Review of Cephalon
BusinessWeek
Teva Pharmaceuticals
Cephalon
Ireland Beckons Biotech Business
Ireland Beckons Biotech Business
Chemical and Engineering News
Ireland
Paladin Considers Options Following Alternate Offer for Afexa
Paladin Considers Options Following Alternate Offer for Afexa
Stock Markets Review
Paladin
Afexa
Valeant Pharmaceuticals
M&A
Debunking Corporate Venture Capital in Biotech
Debunking Corporate Venture Capital in Biotech
Forbes
venture capital
Johnson & Johnson's Xarelto Not a Cure for Pipeline Concerns
Johnson & Johnson's Xarelto Not a Cure for Pipeline Concerns
Seeking Alpha
JNJ
Xarelto
Siga's Setback Promises Gains For PharmAthene
Siga's Setback Promises Gains For PharmAthene
Seeking Alpha
PharmAthene
SIGA technologies
Anything Positive At Enzon?
Anything Positive At Enzon?
Seeking Alpha
Enzon
T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
Yahoo/GlobeNewswire
trastuzumab
T-DM1
breast cancer
Immunogen
8 Underperforming Biotech Stocks Being Bought by the Smart Money
8 Underperforming Biotech Stocks Being Bought by the Smart Money
Seeking Alpha
Amyris
NPS Pharmaceuticals
Targacept
Sequenom
Cadence Pharmaceuticals
Enzon
Dendreon
Incyte
Novartis cutting 2,500 jobs globally
Novartis cutting 2,500 jobs globally
Reuters
Novartis
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »